Cencora Reports Significant Profit Growth in Q1
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 04 2026
0mins
Should l Buy COR?
Source: NASDAQ.COM
- Profit Growth: Cencora, Inc. reported a first-quarter profit of $559.64 million, or $2.87 per share, which is a significant increase from last year's $488.60 million and $2.50 per share, indicating enhanced profitability and competitive strength in the market.
- Adjusted Earnings: Excluding items, Cencora's adjusted earnings reached $797.43 million, or $4.08 per share, demonstrating robust performance in its core business and further solidifying its financial health.
- Revenue Increase: The company's revenue rose 5.5% year-over-year to $85.932 billion, primarily driven by a 5% increase in the U.S. Healthcare Solutions segment and a 9.6% increase in the International Healthcare Solutions segment, showcasing the company's expansion potential in global markets.
- Outlook: Cencora reaffirmed its adjusted earnings guidance for fiscal 2026 at $17.45 to $17.75 per share, up from $16 per share in fiscal 2025, while revising its annual revenue growth outlook from 5%-7% to 7%-9%, reflecting confidence in future growth prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COR
Wall Street analysts forecast COR stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 351.060
Low
400.00
Averages
415.38
High
440.00
Current: 351.060
Low
400.00
Averages
415.38
High
440.00
About COR
Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cencora Prices $3 Billion in Senior Notes Offering
- Financing Scale: Cencora successfully priced $1.5 billion in senior notes across five different maturities, demonstrating strong capital market capabilities despite a slight market reaction with shares down 0.90%.
- Note Rates: The notes range from 3.950% to 5.650%, reflecting market assessments of the company's credit risk, with higher rates potentially increasing future financial costs and impacting profitability.
- Maturity Structure: The notes have maturities ranging from 2029 to 2056, providing a flexible financing structure that helps Cencora meet capital needs in the coming years while supporting its business expansion strategy.
- Market Expectations: The offering is expected to close on February 13, 2026, with Cencora projecting an 11.5%-13.5% operating income growth for 2026, indicating confidence in future performance despite current stock price challenges.
See More
Cencora Prices $1.5 Billion Senior Notes Offering
- Financing Scale: Cencora announced a $1.5 billion offering of five different senior notes with varying maturities, including 3.950% notes due in 2029, 4.250% notes due in 2030, 4.600% notes due in 2033, 4.900% notes due in 2036, and 5.650% notes due in 2056, demonstrating the company's robust capital market financing capabilities.
- Use of Proceeds: The net proceeds from this offering will be used to repay amounts outstanding under Cencora's 364-Day Term Credit Agreement dated January 12, 2026, which was utilized to partially fund Cencora's acquisition of OneOncology, indicating the company's strategic focus on financial integration post-acquisition.
- Underwriting Team: The offering is being managed by a consortium of leading banks including Citigroup, J.P. Morgan, BofA Securities, and Wells Fargo Securities, reflecting strong market confidence in Cencora and its significant position within the industry.
- Compliance Statement: Cencora emphasized that this offering does not constitute an offer to sell or solicit offers to buy the notes, and sales may be unlawful in certain states or jurisdictions, highlighting the company's commitment to compliance with securities laws.
See More
Cardinal Health Shares Surge Following Earnings Report as CEO Discusses Success Factors.
- Fiscal-Year Outlook Increase: Cardinal Health has raised its fiscal-year outlook for the second time in less than a month.
- Positive Financial Performance: The company’s recent adjustments indicate strong financial performance and confidence in future growth.
See More
US Stocks Close Mixed: Nasdaq Hits Seven-Week Low
- Chipmaker Sell-off: Advanced Micro Devices (AMD) plunged over 17% after analysts issued a weak Q1 sales forecast, raising concerns about AI demand and pressuring the broader tech sector, particularly high-flying stocks.
- Super Micro Computer Surge: Super Micro Computer's stock rose more than 13% after forecasting Q3 net sales of at least $12.3 billion, significantly above the consensus estimate of $10.25 billion, indicating strong growth potential in a competitive market.
- Mixed Economic Data: The January ADP employment change rose by 22,000, falling short of the expected 45,000, while the ISM services index remained unchanged at 53.8, exceeding expectations, reflecting the complexities of economic recovery that may influence future monetary policy.
- Improved Market Sentiment: Market sentiment improved following President Trump's signing of a government funding deal, although the agreement only funds the Department of Homeland Security through February 13, highlighting ongoing uncertainties in government operations.
See More
Cencora Reports Strong Q1 2026 Earnings and Raises Guidance
- Acquisition Completed: Cencora has finalized its acquisition of a controlling stake in OneOncology, with CEO Robert Mauch emphasizing that this move will elevate the fiscal 2026 adjusted operating income growth forecast to 11.5%-13.5%, showcasing the company's ongoing strength in the healthcare solutions sector.
- Financial Highlights: In Q1, Cencora reported an adjusted diluted EPS of $4.08, a 9% increase, while consolidated revenue reached $85.9 billion, up 5.5%, driven by solid growth in both U.S. Healthcare Solutions and Other segments, further solidifying the company's market position.
- Outlook Revision: The company raised its fiscal 2026 consolidated revenue growth guidance to 7%-9% and reaffirmed its EPS guidance range of $17.45 to $17.75, reflecting confidence in the sustained performance of the U.S. Healthcare Solutions segment and the expected contributions from OneOncology.
- Risks and Challenges: Despite facing challenges from the loss of a major oncology customer, management expects this issue to ease in Q4, while the International Healthcare Solutions segment is experiencing revenue pressure due to manufacturer price adjustments; however, the company maintains its full-year guidance, demonstrating strong resilience.
See More
US Stocks Waver Amid Mixed Earnings and Tech Rotation
- Market Fluctuations: The S&P 500 Index is up 0.08%, the Dow Jones Industrial Average is up 0.54%, while the Nasdaq 100 Index is down 0.56%, indicating the complexity of market sentiment amid mixed corporate earnings results.
- Divergent Corporate Performance: Super Micro Computer forecasts Q3 net sales of at least $12.3 billion, significantly above the $10.25 billion consensus, leading to a stock price increase of over 15%; conversely, Advanced Micro Devices' weak Q1 sales forecast results in a stock decline of over 13%, reflecting a reassessment of tech stocks.
- Labor Market Signals: The January ADP employment change rose by 22,000, below the expected 45,000, indicating weakness in the labor market that could influence future monetary policy decisions.
- Government Funding Plan: The funding package signed by President Trump extends funding for the Department of Homeland Security through February 13, while other departments are funded until September 30, alleviating concerns over a government shutdown and boosting investor confidence.
See More
Cencora Prices $3 Billion in Senior Notes Offering
- Financing Scale: Cencora successfully priced $1.5 billion in senior notes across five different maturities, demonstrating strong capital market capabilities despite a slight market reaction with shares down 0.90%.
- Note Rates: The notes range from 3.950% to 5.650%, reflecting market assessments of the company's credit risk, with higher rates potentially increasing future financial costs and impacting profitability.
- Maturity Structure: The notes have maturities ranging from 2029 to 2056, providing a flexible financing structure that helps Cencora meet capital needs in the coming years while supporting its business expansion strategy.
- Market Expectations: The offering is expected to close on February 13, 2026, with Cencora projecting an 11.5%-13.5% operating income growth for 2026, indicating confidence in future performance despite current stock price challenges.
See More
Cencora Prices $1.5 Billion Senior Notes Offering
- Financing Scale: Cencora announced a $1.5 billion offering of five different senior notes with varying maturities, including 3.950% notes due in 2029, 4.250% notes due in 2030, 4.600% notes due in 2033, 4.900% notes due in 2036, and 5.650% notes due in 2056, demonstrating the company's robust capital market financing capabilities.
- Use of Proceeds: The net proceeds from this offering will be used to repay amounts outstanding under Cencora's 364-Day Term Credit Agreement dated January 12, 2026, which was utilized to partially fund Cencora's acquisition of OneOncology, indicating the company's strategic focus on financial integration post-acquisition.
- Underwriting Team: The offering is being managed by a consortium of leading banks including Citigroup, J.P. Morgan, BofA Securities, and Wells Fargo Securities, reflecting strong market confidence in Cencora and its significant position within the industry.
- Compliance Statement: Cencora emphasized that this offering does not constitute an offer to sell or solicit offers to buy the notes, and sales may be unlawful in certain states or jurisdictions, highlighting the company's commitment to compliance with securities laws.
See More
Cardinal Health Shares Surge Following Earnings Report as CEO Discusses Success Factors.
- Fiscal-Year Outlook Increase: Cardinal Health has raised its fiscal-year outlook for the second time in less than a month.
- Positive Financial Performance: The company’s recent adjustments indicate strong financial performance and confidence in future growth.
See More
US Stocks Close Mixed: Nasdaq Hits Seven-Week Low
- Chipmaker Sell-off: Advanced Micro Devices (AMD) plunged over 17% after analysts issued a weak Q1 sales forecast, raising concerns about AI demand and pressuring the broader tech sector, particularly high-flying stocks.
- Super Micro Computer Surge: Super Micro Computer's stock rose more than 13% after forecasting Q3 net sales of at least $12.3 billion, significantly above the consensus estimate of $10.25 billion, indicating strong growth potential in a competitive market.
- Mixed Economic Data: The January ADP employment change rose by 22,000, falling short of the expected 45,000, while the ISM services index remained unchanged at 53.8, exceeding expectations, reflecting the complexities of economic recovery that may influence future monetary policy.
- Improved Market Sentiment: Market sentiment improved following President Trump's signing of a government funding deal, although the agreement only funds the Department of Homeland Security through February 13, highlighting ongoing uncertainties in government operations.
See More
Cencora Reports Strong Q1 2026 Earnings and Raises Guidance
- Acquisition Completed: Cencora has finalized its acquisition of a controlling stake in OneOncology, with CEO Robert Mauch emphasizing that this move will elevate the fiscal 2026 adjusted operating income growth forecast to 11.5%-13.5%, showcasing the company's ongoing strength in the healthcare solutions sector.
- Financial Highlights: In Q1, Cencora reported an adjusted diluted EPS of $4.08, a 9% increase, while consolidated revenue reached $85.9 billion, up 5.5%, driven by solid growth in both U.S. Healthcare Solutions and Other segments, further solidifying the company's market position.
- Outlook Revision: The company raised its fiscal 2026 consolidated revenue growth guidance to 7%-9% and reaffirmed its EPS guidance range of $17.45 to $17.75, reflecting confidence in the sustained performance of the U.S. Healthcare Solutions segment and the expected contributions from OneOncology.
- Risks and Challenges: Despite facing challenges from the loss of a major oncology customer, management expects this issue to ease in Q4, while the International Healthcare Solutions segment is experiencing revenue pressure due to manufacturer price adjustments; however, the company maintains its full-year guidance, demonstrating strong resilience.
See More
US Stocks Waver Amid Mixed Earnings and Tech Rotation
- Market Fluctuations: The S&P 500 Index is up 0.08%, the Dow Jones Industrial Average is up 0.54%, while the Nasdaq 100 Index is down 0.56%, indicating the complexity of market sentiment amid mixed corporate earnings results.
- Divergent Corporate Performance: Super Micro Computer forecasts Q3 net sales of at least $12.3 billion, significantly above the $10.25 billion consensus, leading to a stock price increase of over 15%; conversely, Advanced Micro Devices' weak Q1 sales forecast results in a stock decline of over 13%, reflecting a reassessment of tech stocks.
- Labor Market Signals: The January ADP employment change rose by 22,000, below the expected 45,000, indicating weakness in the labor market that could influence future monetary policy decisions.
- Government Funding Plan: The funding package signed by President Trump extends funding for the Department of Homeland Security through February 13, while other departments are funded until September 30, alleviating concerns over a government shutdown and boosting investor confidence.
See More
